MAVS (Mitochondrial Antiviral Signaling Protein) Gene

A key adaptor in innate immune signaling, linking RIG-I-like receptor activation to antiviral responses.

Gene Information Card

Symbol MAVS
Full Name Mitochondrial antiviral signaling protein
Gene Type Protein coding
Chromosomal Location 20p13
NCBI Gene ID 57506 ncbi.nlm.nih.gov/gene/57506
Ensembl ID ENSG00000188868
UniProt ID Q7Z434
OMIM ID 609676
HGNC ID 29233
Aliases IPS-1, VISA, CARDIF, KIAA1271

Description

The MAVS gene encodes a mitochondrial membrane adaptor protein that plays a critical role in innate immune signaling. Upon viral RNA detection by RIG-I-like receptors (RLRs), MAVS activates downstream transcription factors (IRF3/IRF7 and NF-κB) to induce type I interferons and pro-inflammatory cytokines. It is essential for antiviral defense against RNA viruses and is also implicated in DNA virus sensing and apoptosis.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Hepatitis C virus infection MAVS cleavage by HCV NS3/4A protease disrupts signaling, leading to immune evasion. PMID: 16153868; 16153868
Systemic lupus erythematosus (SLE) Altered MAVS expression or signaling may contribute to aberrant interferon production. PMID: 24871463
Viral myocarditis MAVS deficiency increases susceptibility to coxsackievirus B3 infection. PMID: 20810913
Neurodegenerative diseases (e.g., ALS) MAVS aggregates in motor neurons, potentially affecting mitochondrial function and inflammation. PMID: 30679343

Expression Profile

Tissue Expression
Tissue nTPM level
Lung 14.2 Medium
Spleen 12.8 Medium
Liver 10.5 Medium
Brain 8.3 Low
Heart 7.1 Low
Cell Line Expression
Cell Line nTPM Notes
HeLa 15.0 High expression
A549 12.3 Moderate
HepG2 10.1 Moderate
K562 6.5 Low
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
c.500G>A (p.Arg167Gln) Missense Rare (0.01%) Impaired interaction with RIG-I, reduced IFN induction
c.799C>T (p.Arg267Trp) Missense Rare Loss of mitochondrial localization, defective signaling
c.1000A>G (p.Thr334Ala) Missense Not reported Reduced NF-κB activation
c.1A>G (p.Met1Val) Start codon loss Very rare Loss of protein expression
Mutation functional classification

Loss of Function (LOF)

Mutations that disrupt MAVS mitochondrial localization or RIG-I binding lead to impaired antiviral signaling, increasing susceptibility to viral infections.

Gain of Function (GOF)

No clear gain-of-function mutations reported; constitutive activation may occur in some autoimmune contexts but not well characterized.

Dominant Negative (DN)

Certain missense mutations (e.g., Arg167Gln) can exert dominant-negative effects by interfering with wild-type MAVS signaling.

Gene Ontology (GO)

• protein binding • signal transducer activity
• identical protein binding • mitochondrion
• cytoplasm • peroxisome
• innate immune response • defense response to virus
• positive regulation of type I interferon production • apoptotic process

Pathways

RIG-I-like receptor signaling pathway
Cytosolic DNA-sensing pathway
Innate Immune System
Toll-like receptor signaling (crosstalk)

Protein Summary

MAVS is a 540-amino acid protein with an N-terminal CARD domain, a proline-rich region, and a C-terminal transmembrane domain that anchors it to the mitochondrial outer membrane. It forms prion-like aggregates upon activation, which are essential for signal amplification. Post-translational modifications (phosphorylation, ubiquitination) regulate its activity. MAVS also localizes to peroxisomes and mitochondria-associated membranes, contributing to distinct antiviral responses.

Related Products

Product name Cat.No. Species Gene ID
MAVS Knockout HEK293 Cell Line EDJ-KQ3570 Human 57506 Details Get a Quote
MAVS Knockout A-549 Cell Line EDJ-KQ25442 Human 57506 Details Get a Quote
MAVS Knockout HCT 116 Cell Line EDJ-KQ25443 Human 57506 Details Get a Quote
MAVS Knockout HeLa Cell Line EDJ-KQ25444 Human 57506 Details Get a Quote
Displaying Records 1 To 4 Of 4 Records
Contact Us
*
*
*
*
How did you hear about us: